Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED)

✍ Scribed by Aman U. Buzdar; George R. Blumenschein; Terry L. Smith; Charles K. Tashima; Gabriel N. Hortobagyi; H. Yong Yap; Jordan U. Gutterman; Evan M. Hersh; Edmund A. Gehan

• Publisher: John Wiley and Sons
• Year: 1979
• Tongue: English
• Weight: 689 KB
• Volume: 12
• Category: Article
• ISSN: 0022-4790
• DOI: 10.1002/jso.2930120105

✦ Synopsis

A combination of 5-fluorouracil, Adriamycin, cyclophospharnide, and BCG (FAC-BCG) was evaluated as adjuvant treatment in breast cancer patients following surgical excision and/or radiation of first site of recurrent disease.

In a group of 68 patients treated with FAC-BCG, the estimated proportion remaining free of disease at 2 years from first recurrence was 69%, compared t o 24% in 60 historical control patients (P < 0.01).

Estimated 2-year survival rate from first recurrence was 85% for the FAC-BCG patients and 78% for the controls (P = 0.07). This regimen has significantly prolonged the disease-free interval from the first recurrence, but additional follow-up is needed t o determine its effect on long-term survival.